The arithmetic on list price versus negotiated price is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.
List price versus negotiated price versus what you pay posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
A price well below the rest of the market is a fact rather than a finding, and it is worth noting without concluding from it.
Narrowing post #60, because the general version has more than one answer.
Price differences within a market are usually about scale, documentation and logistics rather than about anything mysterious.
The reasoning is more useful than the number, which is why I have shown it.
Everything in post #62 holds. The case it does not cover is the one I have.
My position on list price versus negotiated price is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Post #64 is the version of this I will quote in future. One addition.
List prices versus negotiated prices: the price a pharmaceutical company publishes and the price an insurance company or pharmacy actually pays differ substantially. List price is not what anyone pays.
The confident version of this sentence would be wrong, so here is the hedged one.
A cheaper option that arrives slowly has a cost in the form of running out, and people rarely price that.
Adding thanks rather than a view. I do not have a view worth the space.
Answering the question post #66 raises rather than the one it answers.
Offering a way to settle list price versus negotiated price rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
This follows post #68 rather than contradicting it.
Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers and manufacturers.
That much is documented. The rest is how I have interpreted it.
Worth separating two things that post #66 runs together.
Adding what did not work for me on list price versus negotiated price, since the failures never get written up and they are half the useful information.
Nobody has said the unglamorous part of list price versus negotiated price yet, so: most of the variation is explained by things that are boring to write about and easy to check.
Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented failure of cheaper alternatives.
On post #69 — agreed on the reasoning, with one qualification.
What I would want before treating list price versus negotiated price as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Larger orders shift risk as well as price, because more of your material then comes from one lot.
That is where I would start, not where I would stop.
Comparing a licensed product's price to a research-use-only preparation's price is comparing two different things, and the difference is most of the explanation.
Post #73 describes the usual case. This is about the unusual one.
On list price versus negotiated price: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Reading back through, this was answered upthread and I missed it. My fault.
Post #77 put the caveat in the right place and I want to underline it.
If someone has run list price versus negotiated price properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
Building on post #77 rather than restating it.
Where a price includes consultation, device and follow-up, saying so makes a comparison possible. Most quoted figures do not.
Someone should write this up properly, and it should probably not be me.
Distinguishing three things in the list price versus negotiated price discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Second this, and I would have said it less carefully.
I had written a reply contradicting post #80 and deleted it. Here is what survived.
Bulk pricing tiers are published by some suppliers and negotiated by others, and asking costs nothing.
Price variation between pharmacies: identical prescriptions can cost different amounts at different pharmacies because pharmacies negotiate individually with insurers and manufacturers.
I keep a log of this specifically because memory is unreliable about it.
List prices versus negotiated prices: the price a pharmaceutical company publishes and the price an insurance company or pharmacy actually pays differ substantially. List price is not what anyone pays.
Post #86 is right about the mechanism and I think understates the practical bit.
Where the list price versus negotiated price reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Coming back to post #84, because the follow-up matters more than the original answer.
The cost of an independent submission is worth stating in these threads, because it is the main reason people do not do it.
That is one dataset and I would not build a rule on it.
Landed cost including shipping, fees and currency conversion is what you actually pay, and quotes that look identical frequently are not.